[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1997

Theoretical and Empirical Arguments in Relation to Elective Lymph Node Dissection for Melanoma

Author Affiliations

From the Departments of Medicine and Pathology, University of Washington School of Medicine, Seattle (Dr Piepkorn); the Dermatoepidemiology Unit, Veterans Affairs Medical Center, and Department of Dermatology, Brown University, Providence, RI (Dr Weinstock); and the Dermatopathology Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Barnhill).

Arch Dermatol. 1997;133(8):995-1002. doi:10.1001/archderm.1997.03890440073012
Abstract

Nearly a century of clinical inquiry has failed to incontrovertibly resolve the question of whether elective lymph node dissection is therapeutically beneficial in the management of clinically localized melanoma. The controversy has been renewed by a recent interim update from the Intergroup Melanoma Surgical Program, sponsored by the National Cancer Institute, which has indicated a small survival benefit in a narrowly defined subgroup of patients with primary melanoma. That report stimulated this review of the data, which are presented in the historical context that originally prompted the Intergroup study. Case selection bias has intractably hindered firm conclusions from the numerous nonrandomized studies of elective lymphadenectomy. The two original randomized trials that were executed during the 1970s failed to uncover any significant effect of the procedure on survival. Definitive conclusions from the recent Intergroup report are limited by the likelihood that the observed therapeutic benefits are a chance occurrence resulting from uncorrected multiple subgroup comparisons. It remains uncertain whether elective lymphadenectomy can be therapeutically beneficial in the management of melanoma. Nevertheless, it is clear that the procedure, or preferably sentinel lymphatic mapping with selective lymphadenectomy, can provide clinically relevant prognostic information, as well as the staging data requisite to adjuvant interferon alfa-2b therapy or enrollment into other adjunctive trials for patients at high risk of clinical relapse.

Arch Dermatol. 1997;133:995-1002

×